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Abstract
Background: Glioblastoma is the most common primary brain tumor in adults. Though a lot of research has been
focused on this disease, the causes and pathogenesis of glioblastoma have not been indentified clearly.
Results: We indentified 1,236 significantly differentially expressed genes, and 30 pathways enriched in the set of
differentially expressed genes among 243 tumor and 11 normal samples. We also indentified 97 differentially
expressed microRNAs among 240 tumor and 10 normal samples. 22 of which have been reported to affect
glioblastoma and 50 of which were implicated in other cancers and brain diseases. We regressed gene expression
on microRNA expression in 237 tumor tissues and 10 normal tissues comprehensively. We found two
experimentally validated microRNA targets and 1,094 miRNA-target gene pairs in our datasets which were
predicted by miRanda algorithm, 8 of the target genes were tumor suppressor genes and 3 were oncogenes.
Further function analysis of target genes suggested that microRNAs most frequently targeted genes associated
with Cell Signalling and Nervous System.
Conclusion: We investigated gene and microRNA Expression in Glioblastoma and gave a comprehensive function
study of differential expressed gene and microRNA in glioblastoma patients. These findings gave important clues
to study of the carcinogenic process in glioblastomas.
Background
Glioblastoma Multiforme (GBM) is the most common
and most aggressive type of primary brain tumor,
accounting for 52% of all primary brain tumor cases and
20% of all intracranial tumors [1]. Primary GBM arise
de novo, without any history of pre-existing lower-grade
tumor, whereas secondary GBM have clinical, radiologic,
o rh i s t o p a t h o l o g i ce v i d e n c eo fm a l i g n a n tp r o g r e s s i o n
from pre-existing lower-grade tumor [2]. In the past two
decades, the molecular mechanisms, genetics and paths
to treatment of Glioblastoma have extensively been stu-
died [3]. However, the causes and pathogenesis of
glioblastoma have not been indentified clearly. With the
continuing improvement of high-throughput genomic
technologies, it is now feasible to survey human cancer
genomes comprehensively. The Cancer Genome Atlas
(TCGA) aims to catalogue and discover major cancer-
causing genome alterations in large cohorts of human
tumors through integrated multi-dimensional analyses
[4]. Glioblastoma is the first cancer studied by TCGA.
To identify the genetic alterations in glioblastoma, we
investigated the expression profiles of gene and
microRNA.
MicroRNAs (miRNAs) are single-stranded short cod-
ing RNA molecules of about 22 nucleotides in length,
which usually repress gene expression by binding at the
3’UTR region of target gene [5]. The expressions of
microRNAs are found to be highly different in organ
development and tissue differentiation [6]. Moreover,
many microRNAs have been found to associate with
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gene or tumor suppressor gene [7]. In our study, we
examined the expression levels of 470 human miRNAs
in glioblastoma and indentify a group of microRNAs
whose expression is significantly altered in this tumor.
We also indentified the significantly altered gene expres-
sion and pathways related to glioblastoma.
Results
All types of data were acquired from TCGA project [4]
(http://cancergenome.nih.gov/dataportal/data/about/).
Gene expression microarrays were performed on Affy-
metrix HT Human Genome U133 Array Plate Set by
Massachusetts Institute of Technology (MIT). Level
three data gave calls for genes per sample after Probe-
set-level and Gene-level Robust Multiarray Analysis
(quantile normalization and background corrected) until
the most recent update on Sep. 05, 2008. After calcula-
tion the average expression values for duplicated sam-
ples, finally 243 tumor tissue samples, 10 normal tissues
and 1 cell line sample from glioblastomas patients were
used for differential expression analysis. MicroRNA
expression experiments were performed on Agilent 8 x
1 5 K H u m a nm i c r o R N A - s p e c i f i cm i c r o a r r a yb yU n i v e r s i -
ties of North Carolina (UNC). There are 534 micro-
RNAs (470 human microRNAs) and 240 tumor tissue
samples, 10 normal tissue samples available in level
three data (after quantile normalization and batch
a d j u s t e d )u n t i lt h em o s tr e c e n tu p d a t eo nN o v .1 0 ,
2008. As it is very difficult to get the brain tissue sam-
ples from normal people, the control samples are all
from the adjacent normal tissues of glioblastomas
patients. Thus we focus on detecting the effect of
somatic difference on disease, which is also a common
approach in many other cancer studies. We used 254
samples for gene expression and pathway analysis, 250
samples for microRNA expression analysis, 247 samples
common in microRNA and gene expression datasets for
miRNA targets analysis.
Gene expression analysis
A total of 1,236 genes were identified to be significantly
differentially expressed between tumour and normal tis-
sues. The results were given in Additional file 1. To
further investigate the function of these differentially
expressed genes, we used DAVID [8,9], bioinformatics
resources and pathway analysis [10] for systematic and
integrative analysis of large gene lists. 1,221 of 1,236 dif-
ferentially expressed genes had annotations in DAVID
Functional Annotation Tools. We carried out gene set
enrichment analysis to indentify the most enriched gene
function annotation terms (GO terms) [11] in the list of
1,221 annotated differentially expressed genes. (See
methods for details.) The top ten enriched GO terms in
the list of differentially expressed genes were shown in
Table 1, suggesting these genes were enriched in brain
and mainly associated with Nervous system develop-
ment and function. The detailed information, for exam-
ple, genes which shared the GO terms was given in
Additional file 1.
DAVID also could cluster similar functional GO terms
together. The first two enriched GO term groups in the
differentially expressed gene list were all the function
terms relevant to brain and neuron. They were: 1)
GOTERM Cellular Component including five terms:
neuron projection, cell projection, dendrite, cell soma,
and axon. 53 genes belong to this cluster including
CDK5 , SNCG , UCHL1 , FREQ.
According to NCBI Entrez gene annotation [12], it
was reported that the deregulation of gene CDK5 causes
neuronal death and neurodegenerative diseases. Gene
SNCG encodes a member of the synuclein family of
proteins which are believed to be involved in the patho-
genesis of neurodegenerative diseases. Mutations in this
gene have also been associated with breast tumor devel-
opment. Gene UCHL1 is specifically expressed in the
neurons and in cells of the diffuse neuroendocrine sys-
tem. Mutations in this gene may be associated with Par-
kinson disease. FREQ gene encodes calcium-binding
Table 1 The top ten GO terms most enriched in the differentially expressed gene list
Category Term Annotation Count PValue
Cellular Component GO:0045202 synapse 57 1.39E-15
Biological Process GO:0006810 transport 288 3.10E-14
Biological Process GO:0007268 synaptic transmission 69 8.42E-14
Biological Process GO:0019226 transmission of nerve impulse 75 1.05E-13
Biological Process GO:0051234 establishment of localization 292 6.89E-13
Cellular Component GO:0043005 neuron projection 34 8.64E-13
Biological Process GO:0051179 localization 326 2.36E-12
Cellular Component GO:0016020 membrane 548 8.36E-10
Molecular Function GO:0015075 ion transmembrane transporter activity 100 1.98E-09
Biological Process GO:0007269 neurotransmitter secretion 19 2.62E-09
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tein encoded by this gene is associated with secretory
granules and modulates synaptic transmission and
synaptic plasticity. 2) GOTERM Biological Process
including twenty one terms: synaptic transmission;
transmission of nerve impulse; neurotransmitter secre-
tion; regulated secretory pathway; generation of a signal
involved in cell-cell signaling; regulation of neurotrans-
mitter levels; neurological system process; cell-cell sig-
naling; exocytosis; SNARE binding; secretory pathway
and so on. A total of 336 genes belong to this cluster.
The detailed information for this two GO term groups
were given in Additional file 1.
Pathway analysis
We first used algorithm proposed in TAPPA (Topologi-
cal Analysis of Pathway Phenotype Association) [10] for
pathway analysis. The results revealed that 131 pathways
were significantly associated with glioblastoma (Addi-
tional file 2). The 131 associated pathways belonged to
33 functional groups, among which Cell Signaling, Neu-
roscience, Immunology and Expression were the most
enriched pathway groups. Glioma pathway was the only
significant pathway in the cancer functional group with
P-value= 5.75 × 10
–7. Similar to the GO terms enrich-
ment analysis, we used DAVID Functional Annotation
Tools to indentify which pathways were most enriched
in the list of differentially expressed genes. The 40 sig-
nificant pathways were also given in Additional file 2.
Cell Signaling, Signal Transduction, Apoptosis and Neu-
roscience were the most enriched pathway groups. A
total of 30 significant pathways found by both methods
were shown in Additional file 2. The detailed genes
information involved in the over-represented pathways
was also provided. Long-term potentiation(a Nervous
System pathway) and Calcium signaling pathway(a Sig-
nal Transduction pathway), were the most significantly
enriched pathways with p-value 2.62 × 10
–8 and 3.26 ×
10
–8, respectively. There were 11significant Cell Signal-
ing pathways, 4 significant Apoptosis pathways, 4 signifi-
cant Signal Transduction pathways, 3 significant
Immunology pathways, 3 significant Neuroscience path-
ways and 2 significant Nervous System pathways, (Some
pathways may belong to different functional groups).
The results suggested that the differentially expressed
genes were most involved in signal, apoptosis and neu-
roscience pathways. Take long-term potentiation path-
way as an example, Figure 1 show all the genes in this
pathway, Hippocampal long-term potentiation (LTP) is
a long-lasting increase in synaptic efficacy, is the mole-
cular basis for learning and memory. 3 of the 71 genes
in this pathway were significant over expressed genes
Figure 1 Long term potentiation pathway Figure 1 shows all the genes in this pathway. Significant over expressed genes are highlighted in
blue and under expressed genes in red.
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expressed and were highlighted in red. (One box in the
figure may denote several genes)
Analysis of differential expression of microRNA
A total of 97 microRNAs were significantly differentially
expressed between tumor and normal tissues (Addi-
tional files 3). To examine whether these miRNAs were
associated with glioblastoma, we used miR2Disease [13]
to validate our results (Updated Date: Dec. 19, 2008).
MiR2Disease provides a comprehensive literature
reported resource of miRNA deregulation in various
human diseases. From the data in miR2Disease, 81 of
the 97 significant miRNAs have been reported to associ-
ate with 84 diseases, among them, 72 miRNAs are asso-
ciated with 59 cancers and brain diseases. 22 of those
miRNAs have been reported to induce glioblastoma/
glioblastoma multiforme(GBM)/neuroblastoma (NB) and
the expression pattern of miRNA(up-regulated or down-
regulated) in published literatures is exactly the same as
that in our data. Table 2 gave the p-value, expression
pattern, disease and references for the 22 miRNAs. We
inferred that the other 50 miRNAs which were related
to other cancers and brain diseases may also be impor-
tant for carcinogenesis in brain. However, further
experiment validations were required to confirm our
results. Among the 97 significant miRNAs, 30 miRNAs
were up-regulated and 67 were down-regulated.
To further examine the function of those significant
miRNAs, we need to find the target gene of miRNAs
associated with glioblastomas. So we carried out the
regression analysis for miRNA and gene expression.
The regulation of gene expression by microRNA
miRNA has been thought to promote degradation of
target mRNA or suppress translation of corresponding
protein by matching with mRNA in the 3’-UTR region
[20-23]. There is no doubt that miRNAs perform var-
ious biological functions through regulation of gene
expression. To reveal the mechanisms of how miRNA
regulates gene expression in GBM, we identified target
genes of miRNAs and constructed miRNA target net-
works. Since miRNAs repress the expression of its target
gene, the first step was to test the inverse relationship
between the expression profile of miRNA and that of its
potential targets. To achieve this, we regressed the
expression of target mRNA on the expression of miR-
NAs and select mRNA with significant negative regres-
sion coefficients as miRNA targets. P-value for declaring
significant evidence of miRNA target was 1.00 × 10
–4.
The second step was to conduct sequence analysis
which used sequence complementarities of miRNA and
Table 2 22 MicroRNAs related to glioblastoma/ GBM/ Neuroblastoma
miRNA P-value AvgTumor AvgNorm Exp Disease Ref.
hsa-mir-21 3.08E-24 -0.253536 -4.15408 up GBM [14,15,16]
hsa-mir-23a 1.45E-16 0.0400785 -1.75999 up GBM [14]
hsa-mir-93 5.54E-12 0.0928069 -1.32487 up NB [17]
hsa-mir-25 1.85E-11 -0.278892 -1.7816 up GBM [14]
hsa-mir-155 1.40E-10 0.2248781 -1.32519 up GBM [16]
hsa-mir-92 2.52E-08 -0.089368 -1.30258 up NB [17]
hsa-mir-210 1.74E-07 -0.203768 -1.89154 up GBM [16]
hsa-mir-130a 3.84E-07 -0.024653 -0.83686 up GBM [14]
hsa-mir-106a 1.38E-06 0.0641864 -1.04192 up NB [17]
hsa-mir-17-5p 2.03E-06 0.0488078 -0.97014 up NB [17,18]
hsa-mir-323 5.78E-36 0.1500566 1.345004 down GBM [16]
hsa-mir-137 1.86E-31 0.5176077 3.537668 down GBM [16]
hsa-mir-128a 5.47E-26 0.041749 2.428222 down GBM [16]
hsa-mir-154* 7.62E-23 0.1359234 0.978151 down GBM [16]
hsa-mir-153 1.06E-21 0.0969089 0.406899 down GBM [16]
hsa-mir-132 6.84E-21 0.0656709 1.852984 down GBM [16]
hsa-mir-7 2.53E-18 0.6340624 3.431225 down GBM [19]
hsa-mir-124a 1.76E-17 -0.399441 4.758568 down GBM [16]
hsa-mir-133b 1.36E-11 -0.00609 0.559222 down GBM [16]
hsa-mir-29b 1.42E-10 0.2074092 1.923726 down GBM [16]
hsa-mir-149 2.87E-08 0.1160284 1.636419 down GBM [16]
hsa-mir-133a 9.15E-08 0.0038872 0.398482 down GBM [16]
Exp means whether the expression pattern of microRNA is up-regulated or down- regulated, comparing the average expression value in tumor tissues(AvgTumor)
and average expression value in normal tissues(AvgNorm). GBM: Glioblastoma multiforme, NB: neuroblastoma.
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To achieve this, we use experimentally verified and pre-
dicted miRNA targets data from three miRNAs data-
bases: miR2Disease [13], TarBase [24] and miRBase [25].
MiR2Disease (updated on Dec.19, 2008) and TarBase
(updated on June, 2008) provided experimentally verified
microRNA target genes. MiRBase predicted the target
gene of miRNA by miRanda algorithm [26], where the
predicted target genes and miRNAs could be down-
loaded directly (updated on: Oct.31, 2007).
We compiled 1,236 differentially expressed mRNAs
and 97 differentially expressed miRNAs data in 237
tumor tissue sample and 10 normal tissue samples. We
found two experimentally confirmed results. The litera-
ture reported that the in nasopharyngeal carcinomas
underexpressed hsa-mir-29c (expression fold change
(tumor/normal)=0.20) target overexpressed gene
COL4A1(expression fold change(tumor/normal)=5.24)
[27]. In our result, down-regulated hsa-mir-29c (differ-
entially expressed P-value <5.11 × 10
–12) targets over-
expressed gene COL4A1 (differentially expressed
P-value <3.58 × 10
–6) with regression b = –389.02 and
P= 1.35 × 10
–8. We conclude that hsa-mir-29c is also an
important miRNA in glioblastomas. Another experiment
validated targets gene was LDOC1 targeted by has-miR-
155[28]. The known oncogenic miRNA hsa-miR-155
can regulate a set of target genes including LDOC1, a
regulator of apoptosis [29]. Our results showed that hsa-
miR-155 was over-expressed (differentially expressed
P-value <1.40 × 10
–10) and targets under-expressed gene
LDOC1 (differentially expressed P-value <1.085 × 10
–31)
with regression b = –196.77 and P= 4.00 × 10
–15.W e
inferred that hsa-mir-155 could induce cancer through
regulation of apoptosis gene LDOC1 in glioblastomas.
For predicted targets in miRBase, we found 1,094
matched miRNA-gene pairs including 70 miRNAs and
661 genes (Additional file 4). 44 down-regulated miR-
NAs target 202 overexpressed genes while 26 up-regu-
lated microRNAs target 459 underexpressed genes. The
u pa n dd o w n - r e g u l a t e dm i R NA-gene pairs were shown
in Figure 2 and Figure 3.
The 661 target genes were a subset of the 1236 signifi-
cant differentially expressed genes. We examined which
pathways were these genes enriched in and compared
them with the previous results. 11 pathways were signif-
icant by fisher exact test in DAVID, 8 of which were the
Figure 2 Up-regulated miRNA and their targets Figure 2 show the network of 26 up-regulated miRNAs and 459 under-expressed target
genes.
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tions: Epithelial cell signaling in Helicobacter pylori
infection,Cholera - Infection, Long-term potentiation,
Calcium signaling pathway, Neurodegenerative Diseases,
Long-term depression, Gap junction, Neuroactive
ligand-receptor interaction. Three new enriched path-
ways include Amyotrophic lateral sclerosis (ALS),
Alzheimer’s disease, Wnt signaling pathway. These dif-
ferentially expressed genes were also most involved in
signal and neuroscience pathways.
To investigate the function of the 661 target genes, we
searched the TSGDB [30] (a tumor suppressor gene
database) and DNA-Tumor Suppressor and Oncogene
Database [31] and we found eight tumor suppressor
genes APC, TP53, BIN1, BTG1, CDK2AP1, LDOC1,
RASSF1, WFDC1 and three oncogenes: MCF2, MPL,
THRA.
According to NCBI Entrez gene annotation [12], APC
encodes a tumor suppressor protein that acts as an
antagonist of the Wnt signaling pathway. It is also
involved in other processes including cell migration and
adhesion, transcriptional activation, and apoptosis. TP53
encodes tumor protein p53, which responds to diverse
cellular stresses to regulate target genes that induce cell
cycle arrest, apoptosis, senescence, DNA repair, or
changes in metabolism. BIN1 encodes several isoforms
of a nucleocytoplasmic adaptor protein, one of which
was initially identified as a MYC-interacting protein
with features of a tumor suppressor. Isoforms that are
expressed in the central nervous system may be involved
in synaptic vesicle endocytosis and may interact with
dynanim, synaptojanin, endophilin, and clathrin. LDOC1
is thought to regulate the transcriptional response
mediated by the nuclear factor kappa B (NF-kappaB).
The gene has been proposed as a tumor suppressor
gene whose protein product may have an important role
in the development and/or progression of some cancers.
RASSF1 encoded protein was found to interact with
DNA repair protein XPA. The protein was also shown
to inhibit the accumulation of cyclin D1, and thus
induce cell cycle arrest. WFDC1 gene is mapped to
chromosome 16q24, an area of frequent loss of hetero-
zygosity in many cancers. Owing to its location and a
possible growth inhibitory property of its gene product,
Figure 3 Down-regulated miRNA and their targets Figure 3 shows the network of 44 down-regulated miRNAs and 202 over-expressed target
genes.
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exchange factors that modulate the activity of small
GTPases of the Rho family. Five-prime recombinations
result in the loss of N-terminal codons, producing
MCF2 variants with oncogenic potential.
To further investigate the function of target genes, we
identified the miRNA targeted pathways by right-tail
fisher exact test, which tested enrichment of pathways
in the miRNA target gene set. A total of 83 pathways
targeted by 94 miRNAs were listed in Additional file
5 after Bonferroni correction for multiple tests
(p-values<1.00 × 10
–4). Many of the pathways were tar-
g e t e db ym o r et h a no n em i R N A .W es h o w n2 9p a t h -
ways which were targeted by more than 10 miRNAs in
Figure 4. Long-term potentiation (Nervous System
Figure 4 Down-regulated miRNA and their targets A total of 29 pathways which were targeted by more than 10 miRNAs were shown in
Figure 4. The blue bar indicated that the pathway was targeted by the number of miRNAs. The red bar gave the negative logarithm to the base
10 of average P-value indicating the significance of enrichment of the pathway in miRNA targets.
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Nitric Oxide Signalling (Signalling pathway) was tar-
geted by 74 (the second most) miRNAs. We can see
that the differentially expressed miRNAs most fre-
quently targeted genes in Cell Signalling and Nervous
System. The red bar gave the negative logarithm with 10
base of average p-value indicating the significance of
enrichment of the pathway in the miRNA targets. The
DNA replication pathway and the cell cycle pathway
have the smallest average P-value 7.70 × 10
–9 and the
second smallest P- value 1.17 × 10
–6.P - v a l u e so fL o n g -
term potentiation pathway (7.29 × 10
–6)a n dN i t r i c
Oxide Signalling pathway (9.99 × 10
–6) were also small.
Conclusions
In this paper, we performed detailed analysis of differen-
tial expression of gene and miRNA between tumor tis-
sues and normal brain tissues in glioblastomas. We also
performed gene sets enrichment analysis to find the
enriched GO terms and pathways. Most of the genes
were enriched in Nervous system associated GO terms
and Cell Signaling and Neuroscience associated path-
ways. 22 differentially expressed miRNAs were related
to Glioblastoma multiforme or neuroblastoma. To study
the regulation of gene expression by miRNA, we com-
bined the sequence predicted miRNA targets in miRBase
database, experiment validated miRNA targets in Tar-
Base and miR2Disease database with our predictions
from the gene and miRNA expression profiles and
found 2 experiment validated targets and 1,094 pre-
dicted targets. Further function analysis of target genes
suggests that miRNAs most frequently targeted genes in
Cell Signalling and Nervous System. However, the num-
ber of normal tissues in the studies is small. More sam-
ples are needed for further investigation.
Methods
DAVID bioinformatics resources
The Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) provides a comprehensive
set of functional annotation tools for investigators to
understand biological meaning behind large list of genes
[8,9] (http://david.abcc.ncifcrf.gov/). After inputting large
gene lists, it automatically calculates and identifies
enriched biological themes, particularly GO terms and
pathways; discovers enriched functional-related gene
groups and clusters redundant annotation terms. For
any one GO terms, right tail modified Fisher Exact was
used to determine whether the number of genes with
this GO terms is enriched in the differentially expressed
gene list compared to the number of genes with this
GO terms in all the 19,439 genes on HG-U133A array
(Background). For any one pathway, right tail modified
Fisher Exact was used to determine whether the number
of genes within this pathway is enriched in the differen-
tially expressed gene list compared to the number of
genes within all KEGG or Biocarta pathways. The smal-
ler the p-value was, much more enriched in the GO
terms or pathway than by random chance.
Pathway-based differential expression analysis
We used algorithm proposed in TAPPA (Topological
Analysis of Pathway Phenotype Association) [10] for
pathway analysis. It calculated a Pathway Connectivity
Index for each pathway and then evaluates its correla-
tion to the phenotype variation. Gene connections of
162 KEGG pathways with gene number higher than 8
were collected in that paper and used for PCI calcula-
tion. For those pathways with no edge connections col-
lected, PCI would degenerate into the average of gene
expression values. Totally 501 pathways from KEGG
[32] and Biocarta [33] were assembled in our analysis.
The p-value for declaring significance after Bonferroni
correction for multiple tests was 1 × 10
–4.
Statistical analysis
The differential expression of the gene and microRNA
were tested by T-test and Mann-Whitney Test. The
thresholds for declaring significance after Bonferroni
correction for multiple tests were 4.15 × 10
–6 and 9.36
×1 0
–5, for gene and miRNA respectively. Linear regres-
sion was used to investigate the relationships between
miRNA and gene expressions. The linear model took its
common form: where y is an n-by-1 vector of observa-
tions, such as gene expression. X is an n-by-p matrix of
regressors, such as miRNA expression, b is a p-by-1 vec-
tor of parameters; known as regression coefficient and ε
is an n-by-1 vector of random disturbances. Right-tail
fisher exact test were used to test for the enriched Gene
Ontology Terms, pathways in the datasets. Matlab code
for T-Test, Mann-Whitney Test and linear regression
was attached in Additional files 6.
Additional file 1: The list of 1236 significantly differentially
expressed genesA total of 1236 genes were significantly differentially
expressed by both T-test and Mann-Whitney Test after Bonferroni
correction for multiple tests. The top 10 enriched GO terms and the first
2 significant GO terms clusters were given in sheet 2 and sheet 3,
respectively.
Additional file 2: Lists of significant pathwaysThree sheets gave the
list of 131 significant pathways indentified by TAPPA method, the list of
40 significant pathways indentified by Fisher Exact Test and the list of 30
pathways shared by two methods, respectively.
Additional file 3: The list of 97 significantly differentially expressed
microRNAA total of 97 microRNAs were significantly differentially
expressed by both T-test and Mann-Whitney Test after Bonferroni
correction for multiple tests.
Additional file 4: The predicted microRNA targetsThe 1,094 matched
miRNA-gene pairs including 70 microRNAs and 661 genes predicted by
both our results and miRanda algorithm.
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targeted by 94 microRNAs were listed after Bonferroni correction for
multiple tests.
Additional files 6: Matlab code for statistical analysisWe have
attached the Matlab code for T-Test, Mann-Whitney Test and linear
regression in additional files 6
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